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Abstract. 
 
We show that Bcl-2 expression in skeletal 
muscle cells identifies an early stage of the myogenic 
pathway, inhibits apoptosis, and promotes clonal ex-
pansion. Bcl-2 expression was limited to a small propor-
tion of the mononucleate cells in muscle cell cultures, 
ranging from 
 
z
 
1–4% of neonatal and adult mouse mus-
cle cells to 
 
z
 
5–15% of the cells from the C2C12 muscle 
cell line. In rapidly growing cultures, some of the Bcl-
2–positive cells coexpressed markers of early stages of 
myogenesis, including desmin, MyoD, and Myf-5. In 
contrast, Bcl-2 was not expressed in multinucleate myo-
tubes or in those mononucleate myoblasts that ex-
pressed markers of middle or late stages of myogenesis, 
such as myogenin, muscle regulatory factor 4 (MRF4), 
and myosin. The small subset of Bcl-2–positive C2C12 
cells appeared to resist staurosporine-induced apopto-
sis. Furthermore, though myogenic cells from geneti-
cally Bcl-2–null mice formed myotubes normally, the 
muscle colonies produced by cloned Bcl-2–null cells 
contained only about half as many cells as the colonies 
produced by cells from wild-type mice. This result sug-
gests that, during clonal expansion from a muscle pro-
genitor cell, the number of progeny obtained is greater 
when Bcl-2 is expressed.
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T
 
he
 
 formation of skeletal muscle fibers proceeds
though several distinct stages. In developing verte-
brates, the earliest stages of skeletal muscle forma-
tion occur in the somites, where muscle precursor cells
arise. These precursor cells give rise to myoblasts that sub-
sequently fuse with each other to form multinucleate myo-
fibers (for reviews see Miller, 1992; Stockdale, 1992). At
different stages of this myogenic pathway, cells express
distinct sets of muscle-specific proteins. Desmin, Myf-5,
and MyoD, for example, are expressed at relatively early
stages of the myogenic pathway, whereas myogenin, myo-
genin regulatory factor 4 (MRF4),
 
1
 
 and myosin are ex-
pressed at later stages (George-Weinstein et al., 1993;
Smith et al., 1993, 1994; Wang and Walsh, 1996). Coex-
pression of myogenin with p21 appears to mark a stage in
the myogenic pathway in which the myoblasts are destined
for fusion and terminal differentiation (Skapek et al., 1995;
Wang and Walsh, 1996). The muscle-specific neural cell ad-
hesion molecule (NCAM) isoform, 
 
b
 
7-integrin, nestin, c-met,
and M-cadherin are also expressed by myoblasts (George-
Weinstein et al., 1993; Peck and Walsh, 1993; Irintchev et
al., 1994; Kachinsky et al., 1994; Cornelison and Wold, 1997).
Though c-met, M-cadherin, desmin, Myf-5, and MyoD are
expressed at relatively early stages of myogenesis, these pro-
teins are also found in myogenin-expressing myoblasts and/or
myotubes at later stages of myogenesis (George-Weinstein
et al., 1993; Smith et al., 1993; Kachinsky et al., 1994; Wang
and Walsh, 1996; Cornelison and Wold, 1997). Molecular
markers that are expressed by muscle cells at only the earliest
stages of the myogenic pathway have been lacking.
Because cells in the early stages of myogenesis must be
long-lived in vivo (Webster and Blau, 1990) and pro-
grammed cell death (apoptosis) can be a feature of normal
myogenesis (McClearn et al., 1995) and muscle diseases
(Matsuda et al., 1995; Tidball et al., 1995; Sandri et al.,
1997; Tews and Goebel, 1997; Vachon et al., 1997), we
have examined the expression and function of Bcl-2, an
apoptosis-inhibiting protein (for reviews see Korsmeyer,
1995; Kroemer, 1997; Reed, 1997), in muscle cells. Bcl-2 is
a well-characterized member of a family of proteins that
regulate programmed cell death. When expressed in a
number of nonmuscle cell types, Bcl-2 has the ability to
 
J.A. Dominov and J.J. Dunn contributed equally to this work.
Address all correspondence to Dr. Jeffrey B. Miller, Myogenesis Re-
search Laboratory, Massachusetts General Hospital, 149 13th Street,
Charlestown, MA 02129. Tel.: (617) 726-5754. Fax: (617) 726-8543.
E-mail: Miller@helix.mgh.harvard.edu
 
1. 
 
Abbreviations used in this paper
 
: BrdU, bromodeoxyuridine; MHC, my-
osin heavy chain; MRF, muscle regulatory factor; RT-PCR, reverse tran-
scriptase PCR.
  
The Journal of Cell Biology, Volume 142, 1998 538
 
suppress or delay apoptosis (Korsmeyer, 1995). In myo-
genic cells, however, the expression pattern and function
of Bcl-2 had not been fully determined.
In this work, we show that only a small percentage of
myogenic cells express Bcl-2, and that these Bcl-2–positive
cells resist apoptosis and are at an early stage of a process
leading from muscle progenitor cell to myotube. In addi-
tion, we show that cells from genotypically Bcl-2–null mice
form smaller muscle colonies than cells from wild-type
mice, indicating that Bcl-2 expression is required for nor-
mal growth and/or survival during clonal expansion of
muscle cells. Our finding that Bcl-2 functions to protect
muscle cells from apoptosis suggests that Bcl-2 expression
might be important for long-term survival of muscle cells.
Muscle cell apoptosis is found in several neuromuscular
diseases, including dystrophin deficiency, merosin defi-
ciency, and spinal muscular atrophy (Matsuda et al., 1995;
Tidball et al., 1995; Sandri et al., 1997; Tews and Goebbel,
1997; Vachon et al., 1997). Perhaps muscle cell apoptosis
could be ameliorated by altering Bcl-2 family expression.
In addition, Bcl-2 expression identifies a new stage of the
myogenic pathway, and in cultures that contain cells at
multiple stages of the pathway, Bcl-2 expression can be
used to distinguish mononucleate cells at an early stage
from those at later stages.
 
Materials and Methods
 
Cells
 
C2C12 and Sol8 cells (Yaffe and Saxel, 1977; Blau et al., 1985; Montarras
et al., 1991) were maintained in growth medium (DME with 15% fetal bo-
vine serum, 2 mM 
 
l
 
-glutamine, 10 mM Hepes, pH 7.4, and 100 U/ml peni-
cillin) and induced to form myotubes in differentiation medium (growth
medium with 2% horse serum in place of fetal bovine serum). Cells for
initial primary cultures were obtained from 
 
.
 
6-wk-old adult CD-1 or
C57Bl/6 mice (Charles River Laboratories, Wilmington, MA). For addi-
tional cultures, Bcl-2 (
 
1
 
/
 
2
 
) B6,129-
 
Bcl2
 
tm1Sjk
 
 mice (Veis et al., 1993; Jack-
son Laboratories, Bar Harbor, ME) were interbred, and progeny were
genotyped (Veis et al., 1993) and used for cell preparation. Apoptosis was
induced by transfer to serum-free differentiation medium, with or without
0.5 
 
m
 
M staurosporine, and cell viability was measured by the bulk photo-
metric MTT dye assay of mitochondrial function (Jacobsen et al., 1994).
Myogenic cells from hindlimb muscle of adult and newborn mice were
isolated by trypsinization of tissue (Smith et al., 1993) followed by purifi-
cation on Percoll gradients. Highly enriched myogenic cell populations
containing few nonmyogenic cells were collected from the 35–50% Percoll
interface of either three-step (35, 50, and 70% Percoll) or two-step (35 and
50% Percoll) gradients as described (Bischoff and Heintz, 1994). In some
experiments, nonfractionated cells were also used. Cells were cultured for
up to 8 d on ECL Matrix (Upstate Biotechnology, Lake Placid, NY) in
DME with 15% horse serum, 3% chicken embryo extract, 2 mM 
 
l
 
-glu-
tamine, 10 mM Hepes, pH 7.4, 100 U/ml penicillin, and 1 mM pyruvate.
For high-density cultures, cells were seeded at 3,000–5,000 cells/cm
 
2
 
, and
for clonal cultures, cells were seeded at 5–17 cells/cm
 
2 
 
on the day of isola-
tion. For comparison of Bcl-2–null and wild-type muscle cells, a two-step
plating procedure was used to ensure accuracy of viable cell plating den-
sity. Cells were plated at high density on the day of isolation and then,
within 24 h, were trypsinized from plates. Viable cells (identified by try-
pan blue exclusion) were counted and reseeded at high density (320 cells/
cm
 
2
 
) or clonal density (1.7 cells/cm
 
2
 
). Clonal density plates were fixed with
paraformaldehyde (see below) after 8 d of growth, immunostained for
desmin expression, and counted to determine the number of nuclei per
colony and fusion index. Cell genotypes were determined only after
counting. Cell proliferation in high-density cultures was monitored over 4 d
by scoring cell density using an inverted phase microscope with calibrated
field areas. Bulk population doubling time was estimated between 12 and
60 h after replating during the logarithmic phase of rapid cell growth. Sta-
tistical analysis was by the appropriate unpaired, two-tailed 
 
t 
 
test or non-
parametric Mann-Whitney test using InStat (version 1.12; Graphpad Soft-
ware, San Diego, CA).
 
Immunostaining
 
The hamster mAb, 3F11 (from C. Milliman and S.J. Korsmeyer), is spe-
cific for mouse Bcl-2 (Krajewski et al., 1993) and was used at 25 
 
m
 
g/ml.
Mouse mAbs to myosin heavy chain (F59) and myogenin (F5D), and rab-
bit antisera specific for MyoD, Myf-5, and MRF4 were used as before
(Miller, 1990; Smith et al., 1993; Block et al., 1996). A mouse mAb to
desmin (Cappel Laboratories, Malvern, PA) was used at 1:40 dilution.
Paraformaldehye-fixed and Triton X-100–permeabilized cultures (Smith
et al., 1993) were incubated overnight at room temperature with both a
rabbit antiserum and the Bcl-2 mAb, washed four times for 20 min each
with 0.1% Triton X-100 in PBS, and incubated for 1.5 h at room tempera-
ture with a combination of Texas red– or Cy3-conjugated anti–rabbit IgG
(Jackson ImmunoResearch, West Grove, PA) and fluorescein-conjugated
anti–hamster IgG (Vector Laboratories, Burlingame, CA) at 1.0 
 
m
 
g/ml.
For staining of muscle colonies, cells were stained with a 1:1,000 dilution
of rabbit anti–desmin (Cappel Laboratories) using a horseradish peroxi-
dase–based detection system (Vectastain Elite kit; Vector Laboratories)
with diaminobenzidine substrate (Smith et al., 1994).
To double stain for Bcl-2 and antigens detected by mouse mAbs, cul-
tures were incubated sequentially with (
 
a
 
) the mouse mAb, (
 
b
 
) a lissamine
rhodamine–conjugated Fab fragment of goat anti–mouse IgG (Jackson
ImmunoResearch) at 10 
 
m
 
g/ml, (
 
c
 
) the hamster anti–Bcl-2 mAb, and (
 
d
 
)
fluorescein-conjugated anti–hamster IgG at 1.0 
 
m
 
g/ml. Except where
noted, 
 
$
 
300 Bcl-2–expressing cells in at least two independent cultures
were examined. To double stain for bromodeoxyuridine (BrdU) and Bcl-2,
cultures that had been incubated with 10
 
m
 
M BrdU were fixed at room
temperature for 15 min in 2% paraformaldehyde, permeabilized in 0.1%
Triton X-100 for 15 min, and blocked overnight at 4
 
8
 
C (Smith et al., 1993).
Fixed cultures were rinsed twice with distilled H
 
2
 
O, incubated in 4 N HCl
for 10 min at room temperature, washed twice for 5 min each in PBS,
blocked for 1 h at room temperature, and incubated with anti-BrdU (mAb
G3G4; Developmental Studies Hybridoma Bank, Baltimore, MD) at 37
 
8
 
C
for 1 h at room temperature. After washing, cultures were incubated with
Lissamine rhodamine–conjugated goat anti–mouse (Fab fragment; Jack-
son ImmunoResearch) at 1 
 
m
 
g/ml for 30 min at 37
 
8
 
C, blocked overnight,
and incubated sequentially with anti–Bcl-2 mAb and fluorescein-conju-
gated secondary antibody as above.
 
Immunoblotting
 
Cells were scraped into 1 ml of cold PBS and centrifuged at 12,000 rpm for
15 s. Cell pellets or adult mouse thymuses were immediately lysed in 
 
z
 
2
vol of SDS-PAGE sample buffer, boiled for 4 min, and analyzed by SDS-
PAGE in 15% gels (Kachinsky et al., 1994). After SDS-PAGE, proteins
were electroblotted to a polyvinyl difluoride membrane for 1.5 h at 75 V.
The transfers were dried for 30 min in a vacuum chamber and incubated
for 1 h at room temperature with Bcl-2 mAb at 25 
 
m
 
g/ml in Tris-buffered
saline with 0.3% Triton X-100 and 1% nonfat dried milk. Antibody bind-
ing was visualized using a horseradish peroxidase secondary antibody sys-
tem (ABC-Elite; Vector Laboratories) with chemiluminescent substrate
(ECL; Amersham Corp., Arlington Heights, IL).
 
RNA Analyses
 
For reverse transcriptase (RT)-PCR, 5 
 
m
 
g of total RNA from C2C12 cells
or 0.2 
 
m
 
g poly (A)
 
1
 
 RNA from adult mouse brain were reverse tran-
scribed using oligo (dT) primers. 1/5 of each cDNA product was subjected
to PCR (GeneAmp; Perkin-Elmer Corp, Norwalk, CT). For mouse Bcl-2,
the upstream primer was 5
 
9
 
-AGCCCTGTGCCACCATGTGTC-3
 
9
 
, and
the downstream primer was 5
 
9
 
-GGCAGGTTTGTCGACCTCACT-3
 
9
 
. The
primers are complementary to sequences in two Bcl-2 exons that are sepa-
rated by a large intron in genomic DNA. The amplified cDNA is 480 bp
and includes sequences corresponding to the COOH terminal 153 amino
acids encoded by the 
 
z
 
7.5-kb Bcl-2 mRNA (Negrini et al., 1987). PCR
conditions were: 94
 
8
 
C, 5 min; 30 cycles of 94
 
8
 
C, 1 min, 55
 
8
 
C, 1 min, 72
 
8
 
C 1
min; and 72
 
8
 
C, 10 min. Samples (1/5) of each product were analyzed by
Southern blotting using an 865-bp HindIII-EcoRI fragment of mouse Bcl-2
cDNA (plasmid 3027, S. Korsmeyer) as probe. Northern blots of total
RNA (10 
 
m
 
g/lane) from growing and differentiated C2C12 cells were also
probed with this cDNA. Hybridizations were as described for RNA blots
(Dominov and Miller, 1996) with final washes in 0.2
 
3
 
 SSC, 0.1% SDS,
65
 
8
 
C. 
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Nomenclature
 
As in previous work (Miller and Stockdale, 1986; Smith and Miller, 1992),
myoblasts are considered to be mononucleate cells that express one or
more MRFs, but not skeletal muscle myosin heavy chain (MHC); myo-
cytes are mononucleate cells that express skeletal muscle MHC(s); and
myotubes (or myofibers) are multinucleate, nonmitotic cells that express
skeletal muscle MHC(s). The myogenic pathway is the process by which
mononucleate muscle progenitor cells progress through the myoblast
stage to form myotubes.
 
Results
 
When we immunostained cells of the C2C12 and Sol8
mouse muscle cell lines with an mAb specific for Bcl-2, we
found that a small subset of the mononucleate cells
showed the punctate cytoplasmic staining expected (Kra-
jewski et al., 1993) for Bcl-2 (Fig. 1, 
 
A
 
 and 
 
B
 
, and not
shown). In contrast, none of the multinucleate myotubes
showed Bcl-2 staining (Fig. 1, 
 
A
 
 and 
 
B
 
). The percentage of
Bcl-2–positive cells ranged from 
 
z
 
5–20% for C2C12 cells
and from 
 
z
 
3–5% for Sol8 cells. Similarly, Bcl-2 was ex-
pressed by a small percentage of mononucleate but not
multinucleate cells in primary cultures of adult mouse
muscle cells (Fig. 1, 
 
C
 
 and 
 
D
 
). In primary cell cultures, we
found by two methods that the Bcl-2–expressing cells were
myogenic. First, desmin was coexpressed with most Bcl-
2–positive cells in mouse primary muscle cell cultures, in-
cluding the Bcl-2–positive cell in Fig. 1 
 
C
 
 (not shown),
confirming that these cells were myogenic (George-Wein-
stein et al., 1993). Second, Bcl-2 was expressed by 
 
z
 
2–5%
of the mononucleate cells in clonal, myotube-containing
muscle colonies formed by the progeny of single adult
mouse muscle cells (not shown).
Immunoblotting, Northern blotting, and RT-PCR con-
firmed that Bcl-2 mRNA and protein were expressed in
myogenic cell cultures. On immunoblots probed with anti–
Bcl-2 mAbs, lysates of both mouse thymus, which ex-
presses high levels of Bcl-2 (Haldar et al., 1996), and
C2C12 cells showed identical bands of 
 
z
 
26 kD, as ex-
pected (Haldar et al., 1996) for Bcl-2 protein (Fig. 1 
 
E
 
).
On Northern blots, we detected a transcript of 
 
z
 
7.5 kb,
the size expected (Negrini et al., 1987) for Bcl-2 mRNA, in
both growing and differentiated C2C12 cells (not shown).
When we examined mRNAs from both adult mouse brain,
in which Bcl-2 is expressed (Negrini et al., 1987), and
C2C12 cells, we found that RT-PCR with Bcl-2–specific
primers produced a single DNA band that was the ex-
pected size (480 bp) and hybridized to a Bcl-2 probe (Fig.
1 
 
F
 
).
Upon comparing the expression patterns of Bcl-2 and
several muscle-specific proteins, we found that Bcl-2–posi-
tive C2C12 cells are at a very early stage of myogenic dif-
ferentiation. Specifically, Bcl-2 was not coexpressed with
proteins that mark the middle and late stages of the myo-
genic pathway. Upon examining 
 
$
 
300 Bcl-2–positive
C2C12 cells for each marker, we found no individual cells
in which Bcl-2 was coexpressed with myosin, myogenin,
MRF4, or nestin (Fig. 2, 
 
A–D
 
, and not shown). In primary
cultures, there was also no coexpression of Bcl-2 with
myogenin or myosin (not shown). Myosin and MRF4
mark late stages of C2C12 myogenesis and are largely re-
stricted to myotubes, whereas myogenin and nestin mark
middle stages of myogenesis and are found in many mono-
nucleate myoblasts, as well as in all myotubes (Kachinsky
et al., 1994; Wang and Walsh, 1996).
Next we examined possible coexpression of Bcl-2 with
three markers of earlier stages of the myogenic pathway:
desmin, Myf-5, and MyoD (George-Weinstein et al., 1993;
Smith et al., 1993). As noted above, Bcl-2 was expressed
by only 
 
z
 
10% of the mononucleate C2C12 cells, and we
first examined this small subset of Bcl-2–positive cells for
coexpression of desmin. We found that desmin was ex-
pressed by 
 
z
 
85% of the Bcl-2–positive C2C12 cells as rap-
idly growing cultures neared confluence in growth medium
(Fig. 2, 
 
G
 
 and 
 
H
 
, and Table I), but by only 
 
z
 
15% of the
Bcl-2–positive cells in more quiescent cultures after 3–4 d
in differentiation medium (Table I). As noted previously,
desmin also was coexpressed with most Bcl-2–positive
cells in mouse primary muscle cell cultures, including the
Bcl-2–positive cell in Fig. 1 
 
C
 
 (not shown), confirming that
these cells were myogenic (George-Weinstein et al., 1993).
In double staining experiments, 
 
.
 
99% of growing C2C12
cells expressed desmin, Bcl-2, or both proteins. In particu-
lar, desmin was expressed by the 
 
z
 
90% of all mononucle-
ate cells that were Bcl-2 negative. (The remaining 
 
z
 
10%
of the mononucleate cells were Bcl-2 positive, with the
Figure 1. In myogenic cell cultures, Bcl-2 was expressed by a
small subset of the mononucleate cells (closed arrows) but not in
myotubes (open arrows). Bcl-2 immunostaining (A and C) and
phase contrast (B and D) views of C2C12 (A and B) and mouse
primary (C and D) myogenic cell cultures. Immunoblots (E) and
RT-PCR (F) showed that Bcl-2 protein (z26 kD) and mRNA
(z7.5 kb) were present in C2C12 myogenic cells and in adult
mouse thymus cells. 30, location of 30-kD marker; RT, reverse
transcriptase; GM, growth medium; DM, differentiation medium;
H2O, no RNA control. Bar, 20 mm. 
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patterns of Bcl-2 and desmin coexpression noted above
and in Table I.)
MyoD and Myf-5 were expressed by a much smaller
percentage of the Bcl-2–positive cells than desmin. As
C2C12 cultures approached confluence in growth medium,
only 
 
z
 
20% of the Bcl-2–positive cells expressed MyoD or
Myf-5 (Fig. 2, 
 
E
 
 and 
 
F
 
 
 
insets
 
, and Table I), whereas 
 
z
 
80%
of the Bcl-2–expressing cells did not express either MyoD
or Myf-5 (Fig. 2, 
 
E
 
 and 
 
F
 
, and Table I). When cultures
were switched to differentiation medium, the percentage
of Bcl-2–positive cells that coexpressed either MyoD or
Myf-5 decreased rapidly until, after 4 d in low serum me-
dium, neither MyoD nor Myf-5 was expressed in any of
the Bcl-2–positive cells (Table I). As with desmin, most of
the C2C12 cells that expressed MyoD or Myf-5 were Bcl-2
negative. As C2C12 cells reached confluence in growth
medium, for example, we found that 
 
z
 
50% of the mono-
nucleate cells expressed Myf-5 or MyoD but not Bcl-2,
whereas only 
 
z
 
2% coexpressed Myf-5 or MyoD with Bcl-2.
In clonal cultures of primary cells, 
 
z
 
50% of the Bcl-2–pos-
itive cells also expressed Myf-5 (not shown).
As measured by BrdU incorporation, C2C12 cells that
were Bcl-2 positive were about as likely to be in S-phase as
cells that were Bcl-2 negative. In one experiment, for ex-
ample, we incubated nearly confluent C2C12 cells for 1 d
in growth medium supplemented with 10 
 
m
 
M BrdU and
then double immunostained the cells for BrdU and Bcl-2.
BrdU was incorporated by 
 
z
 
24% (35 of 148 observed) of
the Bcl-2–positive cells and by 
 
z
 
36% (207 of 574) of the
Bcl-2–negative cells.
We next examined how Bcl-2 expression, cell viability,
and differentiation capability were altered by treatments
that induce apoptosis. Because serum-free medium and
staurosporine (a protein kinase inhibitor) induce apopto-
sis in many types of cells (Jacobsen et al., 1994, 1996), in-
cluding Sol8 cells (Mampuru et al., 1996), we switched
growing C2C12 cells into one of three media: differentia-
tion medium with 2% horse serum, serum-free medium, or
serum-free medium with 0.5 
 
m
 
M staurosporine. At 1–2 d
after the switch, the number of viable cells, measured by
mitochondrial function (Jacobsen et al., 1994), had de-
creased in serum-free cultures but had increased in serum-
containing cultures (Fig. 3 
 
a
 
). Pyknotic nuclei, which indi-
cate apoptotic cells (Korsmeyer, 1995; Jacobsen et al.,
1994), were abundant in serum-free cultures after 1–2 d
Figure 2. In growing cultures, the mononucleate C2C12 cells that
express Bcl-2 (A, C, E, and G) did not coexpress myosin (B) or
myogenin (D). About 80% of the Bcl-2–positive cells in growing
cultures did not express MyoD (F), whereas z20% of the Bcl-
2–positive cells did express MyoD (E and F insets). Desmin (H),
as noted in the text, was coexpressed with many, but not all, Bcl-
2–positive cells. Closed, downward pointing arrows indicate cells
that expressed Bcl-2, but not the other tested protein. Open,
downward-pointing arrows indicate cells that coexpressed Bcl-2
and the tested protein. Small, upward-pointing arrows indicate
cells that expressed the tested antigen, but not Bcl-2. Bar, 20 mm.
 
Table I. Percentage of Bcl-2–positive C2C12 Cells That 
 
Coexpressed Additional Muscle-specific Proteins
 
Protein
examined
Culture
condition*
 
Number of Bcl-2
 
1
 
cells examined
 
‡
 
Percentage (number) of
Bcl-2
 
1
 
 cells that coexpressed
the examined protein
 
Desmin GM 314 85.6% (269)
1 d DM 300 69.7% (209)
3 d DM 302 13.9% (42)
4 d DM 300 14.7% (44)
Myf-5 GM 303 21.5% (65)
1 d DM 298 5.4% (16)
2 d DM 317 5.7% (18)
4 d DM 320 0.0% (0)
MyoD GM 380 18.9% (72)
1 d DM 300 3.0% (9)
2 d DM 290 4.8% (14)
4 d DM 305 0.0% (0)
Myogenin All
 
$
 
300 0.0% (0)
MRF4 All
 
$
 
300 0.0% (0)
Myosin All
 
$
 
300 0.0% (0)
 
*As indicated, cells were stained either when they were near confluence in growth
 
medium (
 
GM
 
) or during myotube formation after 1 d, 2–3 d, or 4 d in differentiation
medium (
 
DM
 
).
 
‡
 
Cultures were double immunostained and scanned for Bcl-2–positive cells. Each
Bcl-2–positive cell was examined for coexpression of the tested protein. As described
 
in the text, Bcl-2–positive cells amounted to 
 
z
 
10% of the total number of mononucle-
ate cells at all culture stages.Dominov et al. Bcl-2 and Myogenesis 541
but rare in serum-containing cultures (not shown). The
percentage of C2C12 cells that expressed Bcl-2 remained
at ,20% in serum-containing cultures but was signifi-
cantly (P , 0.01) increased to 50–80% after 2 d in serum-
free culture with or without staurosporine (Fig. 3 b). For
example, after treatment with staurosporine and serum-
free medium for 2 d, the number of viable cells was re-
duced to 10% of the starting number, whereas the percent-
age of Bcl-2–positive cells increased about fourfold to
75% from an initial 16% (Fig. 3). Thus, expression of Bcl-2
is associated with resistance to apoptosis. Some of the
C2C12 cells that survived serum-free medium and stauro-
sporine were able to proliferate and carry out all stages of
myogenesis, including myotube and clonal muscle colony
formation, when returned to serum-containing media (not
shown).
To further examine the relationship between Bcl-2 ex-
pression and myogenic cells, we compared Bcl-2 expres-
sion in early passage and late passage C2C12 cells. At
early passage, almost all cells of lines such as C2C12 are
able to express myogenin and form myotubes, whereas af-
ter repeated passage, differentiation-defective cells accu-
mulate, and the percentage of cells that form myotubes de-
creases (c.f., Wright, 1984; Clegg and Hauschka, 1987;
Rastinejad and Blau, 1993). We compared an early pas-
sage C2C12 line, in which z90% of the cells expressed
myogenin and fused into myotubes, with a late passage
line, in which only z60% of the cells expressed myogenin
and fused into myotubes. In one experiment, we examined
parallel cultures of these two lines as they neared conflu-
ence in growth medium, and we found that Bcl-2 was ex-
pressed by 6.9% (178 of 1,903) of the newly cloned cells,
but by only 4.2% (56 of 1,339) of the multiply passaged
cells. Similarly, after 3 d of differentiation, Bcl-2 was ex-
pressed by 8.1% (116 of 1,437) of the mononucleate newly
cloned cells, but by only 3.1% (26 of 845) of the mononu-
cleate multiply passaged cells. Thus, a higher percentage
of Bcl-2–positive cells was associated with a higher per-
centage of myogenic cells.
We next cloned C2C12 cells and determined the size
and Bcl-2 expression patterns of the resulting muscle colo-
nies. C2C12 cells were allowed 4 d to form muscle colo-
nies, at which time the colonies had a wide variation in
size, ranging from 2 to 184 nuclei per colony. Of 67 colo-
nies examined by immunofluorescence, 33 did not contain
Bcl-2–positive cells and 34 did. The colonies without Bcl-
2–positive cells had an average 6 SE of 44.4 6 6.7 nuclei
and were significantly (P , 0.02) smaller than the colonies
with Bcl-2–positive cells, which had an average of 70.2 6
7.5 nuclei. At this early stage of colony formation, multi-
nucleate cells had not formed.
Finally, to further study the relationship between Bcl-2
expression and myogenesis, we examined myogenesis by
genotypically Bcl-2–null cells and wild-type cells. We
found that Bcl-2–null cells produce myotubes but form
smaller muscle colonies than wild-type cells. We compared
cells obtained from the limbs of newborn Bcl-2 (2/2)
mice with those obtained from wild-type littermates. In
high-density cultures, Bcl-2–null and wild-type cells had
similar log phase rates of cell proliferation in growth me-
dium with population doubling times of z10 h and showed
no differences in myotube formation (not shown). In con-
trast, clonal analyses showed a distinct difference between
Bcl-2–null and wild-type cells.
For clonal analyses, cells were cultured at clonal density
and allowed 8 d to form muscle colonies. Independent
clonal cultures were established from three Bcl-2–null
newborns and four wild-type newborns from two litters.
Cultures were stained for desmin to distinguish desmin-
positive muscle colonies from desmin-negative nonmuscle
colonies. Muscle colonies were examined to determine
both the total number of nuclei in the colony and the per-
centage of nuclei in myotubes.
Muscle colonies formed from Bcl-2 (2/2) cells con-
tained an average 6 SE of 112.6 6 9.7 nuclei (n 5 178),
whereas muscle colonies formed from wild-type cells con-
tained an average 6 SE of 202.8 6 11.8 nuclei (n 5 274), a
highly significant (P , 0.0001) difference. Both Bcl-2–null
and wild-type cells produced colonies with a wide range of
nuclear number, though Bcl-2–null cells produced rela-
tively more small colonies and relatively fewer large colo-
nies than wild-type cells (Fig. 4). In contrast to the differ-
ences in colony size, fusion indices and cloning efficiencies
were similar for Bcl-2–null and wild-type cells. The aver-
age percentage of nuclei within myotubes was 24.9 6 1.3%
for cells without Bcl-2 and 22.3 6 0.9% for wild-type cells,
and the percentage of cloned cells that formed muscle col-
onies ranged, in different experiments, from z20 to 40%
for both Bcl-2–null and wild-type cells.
Discussion
In skeletal muscle cells, our results show that Bcl-2 expres-
sion is a marker for a small subset of cells that are at an
early step in the pathway from muscle progenitor cell to
myotube. Furthermore, Bcl-2 expression inhibits apopto-
sis of these cells and is needed for formation of normal-
sized muscle colonies. The results suggest that Bcl-2
expression may be important for long-term survival of
Figure 3.( a ) The number of
viable C2C12 cells, as mea-
sured by MTT assay of mito-
chondrial function (plotted
on a log scale), was greatly
reduced in serum-free me-
dium (SF) or serum-free
medium with 0.5 mM stauro-
sporine (STS) compared with
growth medium (GM) or low
serum differentiation medium
(2% HS). Means 6 SD were
from quadruplicate wells in
three separate experiments.
(b)  The percentage of C2C12
cells that expressed Bcl-2 (lin-
ear scale) was greater after
incubation in serum-free me-
dium with (STS) or without
(SF) staurosporine than in
control cultures that were
maintained in serum-contain-
ing media (GM or 2% HS, as
in a).The Journal of Cell Biology, Volume 142, 1998 542
muscle progenitor cells and for the regeneration of large
numbers of muscle cells. In addition, Bcl-2 expression
identifies a new stage in the myogenic cell lineage and pro-
vides the first molecular marker that is expressed by mus-
cle cells only at the early stages of the progression from
progenitor cell to myotube. Thus, when analyzing mixed
groups of myogenic cells, it appears that Bcl-2 expression
can be used to directly distinguish mononucleate cells at
early (Bcl-2–positive) and later (Bcl-2–negative) stages of
the pathway.
The observed patterns of muscle gene expression sug-
gest that, as Bcl-2–positive muscle cells and their progeny
progress towards myotube formation, Bcl-2 expression
stops as first Myf-5 and MyoD and then later markers of
terminal differentiation are expressed (Fig. 5). This series
of events, in which mononucleate muscle cells progress
from an early stage when none of the MRFs is expressed
to later stages in which the MRFs are expressed in a de-
fined sequence, has also been demonstrated in mass cul-
tures and by direct analyses of individual muscle satellite
cells (Smith et al., 1993; Cornelison and Wold, 1997). This
proposed sequence of gene expression in early stage mus-
cle cells and myoblasts is supported by our immunostain-
ing and cloning studies. At all stages of culture, including
in newly formed muscle colonies, there were Bcl-2–posi-
tive cells that did not express detectable amounts of any
of the tested muscle-specific genes, including the MRFs,
as well as Bcl-2–positive cells that coexpressed desmin,
MyoD, or Myf-5. However, the percentage of the cells that
coexpressed Bcl-2 with desmin, MyoD, or Myf-5 was much
higher in rapidly growing, low-density cultures (when
myogenin-expressing myoblasts would be produced at a
rapid rate) than in more quiescent, differentiating cultures
(when myogenin-expressing cells would be produced
slowly).
Our results raise the possibility that Bcl-2–positive cells
may include or be identical with muscle stem cells. Bcl-
2–positive muscle cells can divide and appear to produce
myogenin-positive myoblasts as progeny, but they do not
themselves terminally differentiate. These properties are
expected of muscle stem cells (i.e., self-renewing cells that
produce myoblasts as progeny but do not themselves ter-
minally differentiate). The existence of muscle stem cells
has been inferred from cloning studies in vitro (Baroffio
et al., 1996), where the descendants of cloned stem cells in-
clude the new stem cells, myoblasts, and myotubes that
constitute large muscle colonies in vitro. Muscle stem cells
are likely identical to muscle colony–forming cells (Hauschka
et al., 1978; Rutz et al., 1982), as both are defined by the
ability, when cloned, to self-renew and to generate prog-
eny that form myotubes. Estimates of stem cell proportion
range from 1–2% of adult human muscle cells (Baroffio et
al., 1996) to up to 28% of embryonic chicken muscle cells
(Rutz et al., 1982). The percentage of mononucleate mus-
cle cells that expressed Bcl-2 was thus in the same range as
the percentage of stem cells inferred from cloning studies.
Anatomical studies (Polakowska et al., 1994; Krajewski et
al., 1995; Merritt et al., 1995) suggest that stem cells of
some epithelia express Bcl-2. Additional experiments are
needed to purify the Bcl-2–positive cells and determine if
they include or are identical with muscle stem cells.
The mononucleate C2C12 cells that expressed Bcl-2 ap-
peared to resist apoptosis because the cells that survived
induction of apoptosis by serum-free medium and stauro-
sporine were largely those that expressed Bcl-2. Thus, ex-
pression of Bcl-2 from the endogenous promoter appeared
to protect the small subset of Bcl-2–expressing muscle
cells from apoptosis, whereas the Bcl-2–negative muscle
cells were relatively more susceptible. This result is consis-
tent with the apoptosis-inhibiting function of endogenous
Figure 4. When cloned, Bcl-2–null cells produce smaller muscle
colonies than wild-type cells. Clonal cultures were established
from individual newborn mice (n 5 3 for Bcl-2–null, and n 5 4
for wild-type), and the number of nuclei in each resulting muscle
colony was determined. Colony sizes from each individual were
grouped into one of four bins (#100, 101–250, 251–500, or .500
nuclei) and graphed with the four points obtained from each indi-
vidual in the same relative position (e.g., the left-most bar in each
of the four bins was from a single individual). Most of the muscle
colonies produced from Bcl-2–null cells contained fewer than 100
nuclei (top). In contrast, the size distribution of muscle colonies
produced from wild-type cells was shifted to larger sizes, so that
most wild-type colonies contained more than 100 nuclei (bottom).
Figure 5. Proposed stages in the myogenic pathway of satellite
cells, including the expression patterns of Bcl-2 and additional
marker genes. Bcl-2 expression is proposed to precede expression
of the MRFs and myosin. Note also that Bcl-2 expression stops
before myogenin expression, whereas expression of each of the
additional markers is known to continue into the myofiber stage
of differentiation.Dominov et al. Bcl-2 and Myogenesis 543
or ectopic Bcl-2 in numerous other cell types, including
motor neurons and cardiac myocytes (Korsmeyer, 1995;
Michaelidis et al., 1996; Kroemer, 1997; Kirschenbaum
and de Moissac, 1997). Furthermore, ectopic Bcl-2 expres-
sion can protect merosin-deficient myotubes from apopto-
sis (Vachon et al., 1997). Because Bcl-2 expression appears
sufficient to increase the resistance of myoblasts and myo-
tubes to staurosporine-induced apoptosis, we conclude
that other anti–apoptotic Bcl-2 family members that might
normally be expressed after Bcl-2 expression ceases in
myogenic cells are insufficient to prevent death by this sig-
nal. Our results, and those of Vachon et al. (1997), raise
the possibility that diseases with signs of muscle cell apop-
tosis, such as merosin deficiency, dystrophin deficiency,
and spinal muscular atrophy (Matsuda et al., 1995; Tidball
et al., 1995; Vachon et al., 1997), could be ameliorated by
altering Bcl-2 family expression.
The full extent to which muscle cell function is affected
by lack of Bcl-2 remains to be determined. Bcl-2–null
knock-out mice form muscles, but they grow more slowly
after birth than wild-type littermates and have multiple
abnormalities in nonmuscle tissues, including motor neu-
rons (Veis et al., 1993; Nakayama et al., 1994; Kamada et al.,
1995; Michaelidis et al., 1996). As shown here, Bcl-2–null
cells can also produce myotubes in culture, though our col-
ony formation assays show that Bcl-2–null muscle cells
produce smaller muscle colonies than wild-type cells. Be-
cause Bcl-2–null cells form muscle colonies in vitro and
myofibers in vivo, it appears that Bcl-2 is not absolutely re-
quired for the formation or function of cells with the qual-
ities expected of muscle stem cells. Rather, Bcl-2 expres-
sion appears to quantitatively promote clonal expansion,
likely by regulating the survival and/or proliferation of
muscle progenitor cells. A role for Bcl-2 in clonal expan-
sion is consistent with the finding that Bcl-2 is restricted to
muscle cells that are at an early stage of the myogenic
pathway because it is early-stage cells, before myogenin
and p21 expression (Wang and Walsh, 1996), that are
likely to be progenitors of muscle colonies.
Muscle cells and tissues express several members of the
Bcl-2 family in distinct patterns (Krajewski et al., 1994,
1996; Ibi et al., 1996; Sandri et al., 1997), so one or more
members of the Bcl-2 family may be important at all stages
of myogenesis. Adult human, type IIB fast muscle fibers
appear to express Bcl-2 (Ibi et al., 1996). Because we did
not find Bcl-2 in myotubes formed in culture (including
human myotubes; Dunn, J.J., and J.B. Miller, unpublished
observation), this fiber type–specific expression of Bcl-2
may be innervation dependent. In addition, further studies
are needed to determine if Bcl-2 expression identifies cells
at early stages of myogenesis in each of the different lin-
eages of myogenic cells found during development (Miller,
1992; Stockdale, 1992).
It should now be possible to use Bcl-2 promoter expres-
sion as a marker to isolate enriched populations of early
muscle cells for molecular and functional characterization.
It will be important, for example, to identify additional
markers for these cells, to devise assays to measure their
possible stem cell function, to study mechanisms of early
muscle cell–specific gene expression, and to identify mole-
cules that influence early muscle cell division and progress
toward terminal differentiation. Furthermore, myogenic
cells have been used, with uneven success (for review see
Brown and Miller, 1996), as delivery vehicles for gene
therapy. It should soon prove possible to examine whether
success might be improved by using myogenic cells that
are enriched for those at an early stage of the myogenic
pathway.
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